3.0 Eligibility
3.1 Inclusion Criteria
3.11 Age ≥18 years.
3.12 Histologically or cytologically confirmed diagnosis of Multiple Myeloma (MM) as defined in IMWG Criteria or a CD19+ Lymphoproliferative Disorder (LPD) as defined by 2016 WHO classification.
3.13 Provide written informed consent.
3.14 Willingness to provide mandatory bone marrow aspirate specimens for correlative research (see Section 14.0).
3.15 Willingness to provide mandatory hair follicle specimens for correlative research (see Section 17.0).
3.16 Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).
3.17 Willingness to provide saliva samples for research (see Section 14.0).

3.2 Exclusion criteria
3.21 Ineligible for CAR-T therapy.
3.22 Patients diagnosed with myeloid neoplasm before CAR-T therapy.